In this study, we first observed that in DLBCL cell lines, BCL-2 overexpression promoted resistance to drugs inhibiting rRNA synthesis (doxorubicin, actinomycin D [Act D], and CX-5461). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.